Codelivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice

Parasite Immunology

Volumn 38, Issue 4, 2016, Pages 228-235

  Maspi, N ^a   Ghaffarifar, F ^a   Sharifi, Z ^b   Dalimi, A ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

DNA vaccination; IL 12; LeIF; Leishmania major

Indexed keywords

CALCIUM PHOSPHATE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA ELONGATION INITIATION FACTOR; LEISHMANIA VACCINE; PROTOZOAL VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; ELONGATION FACTOR; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; FEMALE; GENETIC TRANSFECTION; HAND INJURY; HEK293 CELL LINE; HUMORAL IMMUNITY; IMMUNITY; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; GENETICS; HUMAN; IMMUNOLOGY; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; PARASITOLOGY; SPLEEN; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; CYTOKINES; FEMALE; HEK293 CELLS; HUMANS; IMMUNITY, HUMORAL; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PEPTIDE ELONGATION FACTORS; PROTOZOAN PROTEINS; SPLEEN; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, DNA;

EID: 84961886892     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12310     Document Type: Article

References (29)

1. Chattopadhyay A & Jafurulla M. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochem Biophys Res Commun 2011; 416: 7-12.
2. Kolodziej H & Kiderlen AF. Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 2005; 66: 2056-2071.
3. Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH & Rafati S. Bivalent DNA vaccination with genes encoding Leishmania major cysteine proteinases type I and II protects mice against infectious challenge. Iran J Biotechnol 2004; 2: 35-43.
4. Ertl PF & Thomsen LL. Technical issues in construction of nucleic acid vaccines. Methods 2003; 31: 199-206.
5. Barhoumi M, Tanner NK, Banroques J, Linder P & Guizani I. Leishmania infantum LeIF protein is an ATP-dependent RNA helicase and an eIF4A-like factor that inhibits translation in yeast. FEBS J 2006; 273: 5086-5100.
6. + T cells. Infect Immun 2007; 75: 4648-4654.
7. Barhoumi M, Garnaoui A, Kaabi B, Tanner NK & Guizani I. Leishmania infantum LeIF and its recombinant polypeptides modulate interleukin IL-12p70, IL-10 and tumour necrosis factor-α production by human monocytes. Parasite Immunol 2011; 33: 583-588.
8. Nahid M, Fatemeh G & Zohreh Sharifi AD. Cloning and constructing a plasmid encoding LeIF gene of Leishmania major fused with GFP gene as a vaccine candidate. West Indian Med J. 2015; doi: 10.7727/wimj.2014.201.
9. Coelho EAF, Tavares CAP, Carvalho FAA, Chaves KF, Teixeira KN, Rodrigues RC, et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 2003; 71: 3988-3994.
10. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
11. Croft SL, Seifert K & Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123: 399-410.
12. Ferreira C, Soares DC, Barreto-Junior CB, et al. Leishmanicidal effects of piperine, its derivatives, and analogues on Leishmania amazonensis. Phytochemistry 2011; 72: 2155-2164.
13. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD & Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011; 15: e525-e532.
14. Santos DO, Coutinho CER, Madeira MF, et al. Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res 2008; 103: 1-10.
15. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003; 16: 397-401.
16. Abdian N, Gholami E, Zahedifard F, Safaee N & Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp Parasitol 2011; 127: 627-636.
17. Skeiky YA, Guderian JA, Benson DR, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995; 181: 1527-1537.
18. Donnelly JJ, Liu MA & Ulmer JB. Antigen presentation and DNA vaccines. Am J Respir Crit Care Med American Thoracic Society New York, NY; 2000; 162(4 Pt 2): S190-S193.
19. Coler RN, Skeiky YA, Bernards K, et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002; 70: 4215-4225.
20. Skeiky YA, Kennedy M, Kaufman D, et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol. 1998; 161: 6171-6179.
21. Re F, Srinivasan R, Igarashi T, Marincola F & Childs R. Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T-cell responses in humans. Exp Hematol Elsevier; 2004; 32: 210-217.
22. Güler ML, Gorham JD, Hsieh CS, et al. Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science 1996; 271: 984-987.
23. Park AY, Hondowicz B, Kopf M & Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol American Association of Immunologists; 2002; 168: 5771-5777.
24. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G & Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235-237.
25. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA & Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol American Association of Immunologists; 1999; 163: 4481-4488.
26. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE & Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177: 1505-1509.
27. Sypek JP, Chung CL, Mayor SE, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177: 1797-1802.
28. Obeng-Adjei N, Hutnick NA, Yan J, et al. DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques. Cancer Gene Ther 2013; 20: 652-662.
29. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE & Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53: 296-302.